Neuralstem Inc. of Rockville, a biotechnology company, reported a second-quarter net loss attributable to common shareholders of $3.6 million, or 8 cents per diluted share, versus a net loss of $5 million, or 12 cents per diluted share, in the year-ago period.

The company reported zero revenue in both years. Analysts surveyed by Thomson Reuters predicted a loss of 11 cents per share in the most recent quarter. Neuralstem is developing products to treat central nervous system disorders with patented stem cell technology.

Powered by Bookmarkify™